half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-24. Anything still debated is marked as such rather than presented as settled.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
The Federal Office for Radiation Protection's monitoring network measures natural radiation exposure through the local dose rate (ODL), expressed in microsieverts per hour (μSv/h). In Germany, the natural ODL ranges from approximately 0.05 to 0.18 μSv/h, depending on local conditions. The ODL monitoring network has been operational since 1973 and currently comprises 1800 fixed, automatically operating measuring points. Its primary function is to provide early warning for the rapid detection of increased radiation from radioactive substances in the air in Germany. Spectroscopic probes have been successfully utilized since 2008 to determine the contribution of artificial radionuclides in addition to the local dose rate, showcasing the network's advanced capabilities. In addition to the ODL monitoring network of the Federal Office for Radiation Protection, there are other federal monitoring networks at the Federal Maritime and Hydrographic Agency and the Federal Institute of Hydrology, which measure gamma radiation in water; the German Meteorological Service measures air activity with aerosol samplers. To monitor nuclear facilities, the relevant federal states operate their own ODL monitoring networks. The data from these monitoring networks are automatically fed into the Integrated Measurement and Information System (IMIS), where they are used to analyze the current situation. Many countries operate their own ODL monitoring networks to protect the public. In Europe, these data are collected and published on the EURDEP platform of the European Atomic Energy Community.
== Honours and awards == 2000 – Human Frontier Science Program Long-Term Postdoctoral Fellowship. 2004 – Career Development Award, Human Frontier Science Program 2007 – Starting Grant, European Research Council 2013 – Rector's Prize for Excellence in Research and Teaching, Hebrew University of Jerusalem 2015 – Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research 2018 – Michael Milken Prize for Excellence in Teaching.
==== Dopaminergic pathway and reward suppression ==== The mesolimbic dopaminergic circuit functions as a substrate for KOR-regulated mood homeostasis. Dynorphin is synthesized and released by dopamine D1 receptor-expressing medium spiny neurons within the NAcc, establishing a local negative feedback loop that suppresses dopamine release. KOR activation on dopamine terminals inhibits dopamine release through multiple mechanisms: increased potassium conductance via G protein-coupled inward-rectifier potassium (GIRK) channels, suppression of calcium entry, activation of protein kinase C-β (PKCβ), c-Jun N-terminal kinase (JNK), and ERK, as well as facilitation of dopamine transporter (DAT) function through ERK1/2-dependent pathways that accelerate dopamine reuptake. Additionally, KOR activation on local dynorphin-expressing neurons produces presynaptic inhibition of both glutamatergic and GABAergic afferents onto D1 receptor-expressing medium spiny neurons, with preferential suppression of amygdala inputs to D1-MSNs while facilitating integration of hippocampal/amygdalar inputs onto D2 receptor-expressing neurons through disinhibition. In the caudal NAcc shell, KOR-induced dopamine suppression triggers anxiogenic behaviors accompanied by reduced locomotor activity. Conversely, in the rostral shell, KOR activation produces attenuated dopaminergic suppression with diminished aversive behavioral consequences.
6,14-Endoethenotetrahydrooripavine is the central nucleus, or backbone, of a class of morphinan opioids known as the Bentley compounds and may be considered their "privileged scaffold". These include but are not limited to etorphine and buprenorphine. They usually have thebaine or oripavine as their precursor in their syntheses (and are thus termed "thevinols" and "orvinols", respectively).
Sources: en.wikipedia.org
Myxofibrosarcoma (MFS), although a rare type of tumor, is one of the most common soft tissue sarcomas, i.e., cancerous tumors, that develop in the soft tissues of elderly individuals. Initially considered to be a type of histiocytoma termed fibrous histiocytoma or myxoid variant of malignant fibrous histiocytoma, Angervall et al. termed this tumor myxofibrosarcoma in 1977. In 2020, the World Health Organization reclassified MFS as a separate and distinct tumor in the category of malignant fibroblastic and myofibroblastic tumors. MFS tumors are often treated by surgical resection. However, these tumors have high recurrence rates at the sites of their resections. Local recurrences followed by surgical resections may be repeated multiple times but during these cycles MFS tumors often progress from a lower grade to a higher more aggressive grade, metastasize, and become life-threatening. An uncommon variant of the MFS tumors termed epithelioid myxofibrosarcoma is even more likely to follow an aggressive, recurrent, metastasizing, and life-threatening course than the more common form of the MFS tumors.
Exercise intolerance, Abnormal muscle fatigue (premature fatigue and/or inability to get into second wind), muscle pain (myalgia), cramping or muscle stiffness during and/or after exercise, Shortness of breath (dyspnea), or rapid breathing (tachypnea), or heavy breathing (hyperpnea), or both (exercise hyperventilation) Inappropriate rapid heart rate in response to exercise (tachycardia), Exaggerated cardiorespiratory (breath and heart rate combined) response to exercise (dyspnea/tachypnea/hyperpnea and tachycardia), Exercise-induced myogenic hyperuricemia (exercise-induced accelerated breakdown of purine nucleotides in muscle via adenylate kinase reaction and purine nucleotide cycle), Transient muscle contracture or pseudomyotonia (like a really bad cramp that can last for hours, which is myogenic and EMG silent), May have progressive muscle weakness, May have a pseudoathletic appearance (hypertrophy or pseudohypertrophy) especially of the calves, Reddish-brown urine (myoglobinuria) and considerable breakdown of muscle tissue (rhabdomyolysis). The degree of symptoms varies greatly from person to person and is dependent on the severity of enzymatic or transport protein defect. In extreme cases it can lead to rhabdomyolysis. The symptoms experienced also depend on which metabolic pathway is impaired, as different metabolic pathways produce ATP at different time periods during activity and rest, as well as the type of activity (anaerobic or aerobic) and its intensity (level of ATP consumption).
Official diplomatic recognition by other countries was key for Rhodesia as it was the only way it could regain the international legitimacy it had lost through UDI. Recognition by the UK itself through a bilateral settlement would be the "first prize", in Smith's words, as it would end sanctions and constitutional ambiguity and make foreign acceptance, at least in the West, far more likely. Considering their country a potentially important player in the Cold War as a "bastion against communism" in southern Africa, the RF posited that some Western countries might recognise UDI even without a prior Anglo-Rhodesian rapprochement. Specifically, it expected diplomatic recognition from South Africa and Portugal, and thought that France might recognise Rhodesia to annoy Britain and create a precedent for an independent Quebec. But although South Africa and Portugal gave economic, military and limited political support to the post-UDI government (as did France and other nations, to a lesser extent), neither they nor any other country ever recognised Rhodesia as a de jure independent state. Rhodesia's unsuccessful attempts to win Western support and recognition included offers to the US government in 1966 and 1967, ignored by Lyndon B. Johnson's administration, to provide Rhodesian troops to fight alongside the Americans and other anti-communist forces in Vietnam.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.